Payload Information

General Information of This Payload
Payload ID
PAY0LGKPJ
Name
AZ-1508
Synonyms
Tubulysin AZ-1508; 1817736-04-1; UNII-1Y3DZ3604R; 1Y3DZ3604R; AZ 1508; AZ-1508; AZ1508; SCHEMBL17157189; AKOS040743569; HY-128962; CS-0102877; (2S,4R)-4-[[2-[(1R,3R)-1-acetyloxy-3-[[(2S,3S)-2-[[(2R,4R)-1,4-dimethylpiperidine-2-carbonyl]amino]-3-methylpentanoyl]-ethylamino]-4-methylpentyl]-1,3-thiazole-4-carbonyl]amino]-5-[4-[[(2S)-6-amino-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]hexanoyl]amino]phenyl]-2-methylpentanoic acid
   Click to Show/Hide
Target(s) Microtubule (MT)
 Target Info 
Structure
Formula
C56H85N9O11S
Isosmiles
CC[C@H](C)[C@@H](C(=O)N(CC)[C@H](C[C@H](C1=NC(=CS1)C(=O)N[C@@H](CC2=CC=C(C=C2)NC(=O)[C@H](CCCCN)NC(=O)CCCCCN3C(=O)C=CC3=O)C[C@H](C)C(=O)O)OC(=O)C)C(C)C)NC(=O)[C@H]4C[C@@H](CCN4C)C
PubChem CID
118431298
InChI
InChI=1S/C56H85N9O11S/c1-10-36(6)50(62-53(72)45-29-35(5)25-28-63(45)9)55(73)64(11-2)44(34(3)4)32-46(76-38(8)66)54-61-43(33-77-54)52(71)59-41(30-37(7)56(74)75)31-39-19-21-40(22-20-39)58-51(70)42(17-14-15-26-57)60-47(67)18-13-12-16-27-65-48(68)23-24-49(65)69/h19-24,33-37,41-42,44-46,50H,10-18,25-32,57H2,1-9H3,(H,58,70)(H,59,71)(H,60,67)(H,62,72)(H,74,75)/t35-,36+,37+,41-,42+,44-,45-,46-,50+/m1/s1
InChIKey
DONIIAXVJUFSOY-FJTITLMZSA-N
IUPAC Name
(2S,4R)-4-[[2-[(1R,3R)-1-acetyloxy-3-[[(2S,3S)-2-[[(2R,4R)-1,4-dimethylpiperidine-2-carbonyl]amino]-3-methylpentanoyl]-ethylamino]-4-methylpentyl]-1,3-thiazole-4-carbonyl]amino]-5-[4-[[(2S)-6-amino-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]hexanoyl]amino]phenyl]-2-methylpentanoic acid
Pharmaceutical Properties
Molecule Weight
1092.4
Polar area
308
Complexity
2000
xlogp Value
3.5
Heavy Count
77
Rot Bonds
33
Hbond acc
15
Hbond Donor
6
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
T-D4-1508 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.11 ng/mL
Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000 ng/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
T-D6-1508 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.14 ng/mL
Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000 ng/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
T-D8-1508 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.16 ng/mL
Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000 ng/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
T-D2-1508 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
6.40 ng/mL
Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000 ng/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Moderate HER2 expression (HER2 ++)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Breast adenocarcinoma MDA-MB-361 cells CVCL_0620
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 10.00 ug/mL Low HER2 expression (HER2 +)
Method Description
Tumor cell lines were seeded in 96-well culture plates at 2000, 1600 and 5000 per well in 80 l, respectively, allowed to adhere overnight and treated on the following day with 20 l of serial dilutions of ADCs in duplicate.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
References
Ref 1 Design and Validation of Linkers for Site-Specific Preparation of Antibody-Drug Conjugates Carrying Multiple Drug Copies Per Cysteine Conjugation Site. Int J Mol Sci. 2020 Sep 19;21(18):6882. doi: 10.3390/ijms21186882.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.